

## FACT SHEET

### *About IDT*

- IDT, an operating company within Danaher Corporation's (NYSE: DHR) Life Sciences platform, was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Leuven, Belgium; and Singapore.
- IDT leads the industry in the manufacture of custom oligonucleotides for molecular biology applications. IDT has also developed proprietary technologies for genomics applications, such as Next Generation Sequencing, CRISPR genome editing, qPCR, and RNA interference.
- IDT serves more than 130,000 life sciences researchers in more than 100 countries.
- IDT has approximately 1,500 employees worldwide.
- IDT's recent history includes providing products to diagnostic test manufacturers developing tests for H1N1, Ebola virus, and Zika virus.
- IDT has already shipped synthetic genes for use in the pursuit of coronavirus vaccines, as well as customized oligonucleotide probes and primers that will facilitate more sensitive and accurate detection of COVID-19.

### *IDT's COVID-19 Response*

- On January 28, 2020, IDT announced it was accepting pre-orders from the global public health and research communities for qPCR primers and probes designed to aid researchers in the detection of COVID-19. IDT started fulfilling orders on February 10.
- The primer and probe kits are manufactured in IDT's Coralville, Iowa headquarters. The primer and probe kits are manufactured under ISO 13485:2016 conditions in a suite of cleanrooms designed to prevent synthetic template contamination. The primer and probe kits are formulated to meet CDC's recommended primer-to-probe ratio.
- IDT is manufacturing primer and probe kits that can be used as a component of the CDC testing protocol for which the CDC obtained Emergency Use Authorization (EUA) for the diagnosis and detection of COVID-19.

- The CDC and FDA first contacted IDT on February 25 to discuss its ability to support the CDC EUA testing protocol. IDT shipped primer and probe kits to the CDC the same day for delivery on February 26. On March 2, the FDA included lot#0000500383 as the first lot of primers and probe kits qualified under the CDC's EUA. Subsequently, the CDC has continued to qualify additional lots. Current information on qualified lots is available on the IDT website. (<https://www.idtdna.com/pages/landing/coronavirus-research-reagents#media>).
- In May 2020 IDT broadened its capacity and customer support of COVID-19 products with the opening of a new manufacturing facility in Research Triangle Park, North Carolina. In addition to serving customers in Research Triangle Park, the North Carolina facility will support next-day service to a number of cities, including Baltimore, Boston, Houston, New York City, and Philadelphia.
- As of June 12, 2020, IDT has shipped primer and probe kits sufficient to enable more than 35 million tests to be conducted in the US pursuant to the CDC EUA testing protocol.
- The CDC EUA testing protocol for the diagnosis and detection of COVID-19 requires special testing equipment and is not a direct to consumer test. IDT's primer and probe kits are made available to the CDC and other qualified institutions who carry out disease diagnosis as a routine matter of their business. These tests require specific equipment and consumable reagents in order to complete the testing.
- IDT expanded its coronavirus product line in April 2020 with the addition of primer-probe kits equivalent to the primer and probe ratios described in the WHO panel. The World Health Organization (WHO) testing protocol has been use more routinely in Europe and Asia.
- A strategic partnership with Sherlock Biosciences was announced in June 2020 to enable the large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit for the detection of the coronavirus that causes COVID-19. The Sherlock kit is the first CRISPR-based diagnostic test to receive EUA for the detection of SARS-CoV-2. IDT is supporting the manufacturing of the kit by supplying several key components.

#### Media contacts:

IDT Public Relations [idtpr@idtdna.com](mailto:idtpr@idtdna.com)